Keep an eye at 86-87, page-5

Agreed. I think the short term outlook looks a little concerning though. Unless specialty grows even more rapidly than it has (and with Tolsura this is a possibility). Looks like key generic brands will lose share with competition - the main offset we've been waiting for is Nuvaring which is now more than 12 months away. I'm a huge believer in the long term of this company. But I don't see the price doing much in the short term. Hope I am wrong, as I was well wrong with my previous predictions too! Good luck to all holders.